{'fraction_non_alphanumeric': 0.032981530343007916, 'fraction_numerical': 0.009234828496042216, 'mean_word_length': 6.779487179487179, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high‐risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy

Abstract: Systemic scedosporiasis due to the anamorph or asexual form Scedosporium apiospermum (Pseudallescheria boydii) has become an important cause of opportunistic mycosis, especially in patients undergoing high‐risk hematopoietic stem cell transplantation. We report a case of rapidly progressive cerebellar hyalohyphomycosis due to Scedosporium apiospermum in an allogeneic marrow graft recipient receiving treatment for severe graft‐versus‐host disease. This fatal breakthrough intracranial abscess, due to amphotericin B‐resistant (minimum inhibitory concentration > 16 µg/ml) mold, developed during the course of systemic antifungal therapy given for multicentric pulmonary aspergillosis. Despite treatment with high‐dose Abelcet® (10 mg/kg daily), free amphotericin B was not detected in postmortem cerebellar tissue. A broad‐spectrum triazole‐based agent (voriconazole/UK‐109, 496 – Vfend®), and a novel fungal cell wall inhibitor, an echinocandin/pneumocandin analog (caspofungin/MK‐0991 – Cancidas®), which exhibit excellent in vitro activity against most clinical Pseudallescheria boydii–Scedosporium apiospermum isolates, have recently become available in the United States and may provide much needed treatment options for patients at risk.